SG11202112562XA - Compound for treating gout or hyperuricemia - Google Patents
Compound for treating gout or hyperuricemiaInfo
- Publication number
- SG11202112562XA SG11202112562XA SG11202112562XA SG11202112562XA SG11202112562XA SG 11202112562X A SG11202112562X A SG 11202112562XA SG 11202112562X A SG11202112562X A SG 11202112562XA SG 11202112562X A SG11202112562X A SG 11202112562XA SG 11202112562X A SG11202112562X A SG 11202112562XA
- Authority
- SG
- Singapore
- Prior art keywords
- hyperuricemia
- compound
- treating gout
- gout
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847519P | 2019-05-14 | 2019-05-14 | |
| PCT/US2020/032725 WO2020232156A1 (en) | 2019-05-14 | 2020-05-13 | Compound for treating gout or hyperuricemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112562XA true SG11202112562XA (en) | 2021-12-30 |
Family
ID=73288915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112562XA SG11202112562XA (en) | 2019-05-14 | 2020-05-13 | Compound for treating gout or hyperuricemia |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220242841A1 (en) |
| EP (1) | EP3968989A4 (en) |
| JP (1) | JP2022533958A (en) |
| KR (1) | KR20220016105A (en) |
| CN (1) | CN113874014A (en) |
| AU (1) | AU2020274165A1 (en) |
| BR (1) | BR112021022843A2 (en) |
| CA (1) | CA3140412A1 (en) |
| IL (1) | IL288034A (en) |
| MA (1) | MA55973A (en) |
| MX (1) | MX2021013980A (en) |
| SG (1) | SG11202112562XA (en) |
| TW (1) | TW202108561A (en) |
| WO (1) | WO2020232156A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL298833A (en) * | 2020-06-10 | 2023-02-01 | Arthrosi Therapeutics Inc | Methods for treating or preventing chronic kidney disease |
| WO2023058975A1 (en) * | 2021-10-07 | 2023-04-13 | (주)이노보테라퓨틱스 | Pharmaceutical composition for inhibiting hsp47 including benzofuranyl hydroxyphenyl methanone derivative |
| TW202330485A (en) * | 2021-12-02 | 2023-08-01 | 美商安索治療公司 | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| TW202334103A (en) * | 2021-12-30 | 2023-09-01 | 美商安索治療公司 | Preparation of a compound for the treatment of gout or hyperuricemia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9962362B2 (en) * | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| JP2019524747A (en) * | 2016-07-18 | 2019-09-05 | アースローシ セラピューティクス，インク． | Compounds, compositions and methods for treating or preventing symptoms associated with gout or hyperuricemia |
| WO2019195118A1 (en) * | 2018-04-03 | 2019-10-10 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
| KR20210100677A (en) * | 2018-12-06 | 2021-08-17 | 아쓰로시 테라퓨틱스, 인크. | A crystalline form of a compound for the treatment or prophylaxis of gout or hyperuricemia |
-
2020
- 2020-05-13 MX MX2021013980A patent/MX2021013980A/en unknown
- 2020-05-13 TW TW109115899A patent/TW202108561A/en unknown
- 2020-05-13 CN CN202080035809.1A patent/CN113874014A/en active Pending
- 2020-05-13 JP JP2021568229A patent/JP2022533958A/en active Pending
- 2020-05-13 SG SG11202112562XA patent/SG11202112562XA/en unknown
- 2020-05-13 BR BR112021022843A patent/BR112021022843A2/en unknown
- 2020-05-13 WO PCT/US2020/032725 patent/WO2020232156A1/en unknown
- 2020-05-13 EP EP20804806.6A patent/EP3968989A4/en active Pending
- 2020-05-13 MA MA055973A patent/MA55973A/en unknown
- 2020-05-13 US US17/610,673 patent/US20220242841A1/en active Pending
- 2020-05-13 CA CA3140412A patent/CA3140412A1/en active Pending
- 2020-05-13 KR KR1020217041035A patent/KR20220016105A/en active Search and Examination
- 2020-05-13 AU AU2020274165A patent/AU2020274165A1/en active Pending
-
2021
- 2021-11-11 IL IL288034A patent/IL288034A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3968989A1 (en) | 2022-03-23 |
| CA3140412A1 (en) | 2020-11-19 |
| BR112021022843A2 (en) | 2022-03-03 |
| EP3968989A4 (en) | 2022-12-28 |
| CN113874014A (en) | 2021-12-31 |
| TW202108561A (en) | 2021-03-01 |
| KR20220016105A (en) | 2022-02-08 |
| MX2021013980A (en) | 2022-04-01 |
| JP2022533958A (en) | 2022-07-27 |
| IL288034A (en) | 2022-01-01 |
| WO2020232156A1 (en) | 2020-11-19 |
| AU2020274165A1 (en) | 2022-01-06 |
| US20220242841A1 (en) | 2022-08-04 |
| MA55973A (en) | 2022-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288034A (en) | Compound for treating gout or hyperuricemia | |
| EP3348557A4 (en) | Compound for treating or preventing hyperuricemia or gout | |
| IL283663A (en) | Crystalline forms of a compound for treating or preventing gout or hyperuricemia | |
| PT3484862T (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| IL283665A (en) | Methods for treating or preventing gout or hyperuricemia | |
| IL289617A (en) | Heterocyclic compounds | |
| IL289595A (en) | Heterocyclic compounds | |
| IL290087A (en) | Inhibitor compounds | |
| SG11202110534QA (en) | Cd73 inhibitors | |
| GB201914860D0 (en) | Inhibitor compounds | |
| GB201909468D0 (en) | Compounds for treating cancer | |
| IL291322A (en) | Acrylamide compounds | |
| EP3981469A4 (en) | Therapeutic for gout or hyperuricemia | |
| PL4010303T3 (en) | Compound for reinforcing surface treatment | |
| ZA202103106B (en) | Heterocyclic compounds for the treatment of epilepsy | |
| GB201915191D0 (en) | Novel heterocyclic compounds | |
| GB201905328D0 (en) | Inhibitor compounds | |
| GB201804763D0 (en) | Gout treatment | |
| IL290319A (en) | Compound for combination treatment | |
| EP3782603C0 (en) | Pharmaceutical composition for treating gout | |
| IL288323A (en) | Dopamine-β-hydroxylase inhibitors | |
| IL278984A (en) | Safinamide for treating myotonia | |
| IL284416A (en) | Disulphide compounds | |
| IL284668A (en) | Methods for treating schizophrenia | |
| GB202007652D0 (en) | Compounds for treating covid-19 |